Marc Lalancette

Tessier C, LeBlanc R, Roy J, Trudel S, Côté J, Lalancette M, Boudreault JS, Lemieux-Blanchard É, Kaedbey R, Pavic M

Poor outcome despite modern treatments: A retrospective study of 99 patients with primary and secondary plasma cell leukemia

Cancer Med, 13 (17), 2024.

Résumé | Liens:

Morin L, Grenier LP, Foucault N, Lévesque É, Fabi F, Langlais EL, Sebastianelli A, Lavoie M, Lalancette M, Plante M, Singbo MNU, Castonguay V

Comparison of Weekly Paclitaxel Regimens in Recurrent Platinum-Resistant Ovarian Cancer: A Single Institution Retrospective Study

Curr Oncol, 31 (8), 2024.

Résumé | Liens:

Pelland AA, Deschênes-Simard X, Savard X, Giguère P, Spillane D, Barabé F, Laroche V, Munger M, Gallagher G, Marcoux N, Cantin G, Chénard-Poirier M, Delage R, Lalancette M, Veilleux O, Assouline SE, Lemieux C

Outcomes of adults with refractory or relapsed acute myeloid leukemia treated with azacitidine and venetoclax compared to other therapies: a multicenter retrospective study

Leuk Lymphoma, 2024.

Résumé | Liens:

Monteith BE, Venner CP, Cheung MC, Pater J, Shepherd L, Richardson H, Reece D, Gul E, Lalancette M, Castonguay V, Kukreti V, Tiedemann R, Phua C, Bhella S, Dudebout J, Sherry M, Yen H, Chen BE, Hay AE

A descriptive cost-analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high-dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma

Eur J Haematol, 107 (3), 2021.

Résumé | Liens:

Venner CP, LeBlanc R, Sandhu I, White D, Belch AR, Reece DE, Chen C, Dolan S, Lalancette M, Louzada M, Kew A, McCurdy A, Monteith B, Reiman T, McDonald G, Sherry M, Gul E, Chen BE, Hay AE

Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN-003/MYX.1 single arm phase II trial

Am J Hematol, 96 (5), 2021.

Résumé | Liens:

Monteith BE, Venner CP, Reece DE, Kew AK, Lalancette M, Garland JS, Shepherd LE, Pater JL, Hay AE

Drug-induced Thrombotic Microangiopathy with Concurrent Proteasome Inhibitor Use in the Treatment of Multiple Myeloma: A Case Series and Review of the Literature

Clin Lymphoma Myeloma Leuk, 20 (11), 2020.

Résumé | Liens:

Savoie ML, Bence-Bruckler I, Huebsch LB, Lalancette M, Hillis C, Walker I, Lipton JH, Forrest DL, Kim DDH

Canadian chronic myeloid leukemia outcomes post-transplant in the tyrosine kinase inhibitor era

Leuk Res, 73 , 2018.

Résumé | Liens:

Dimopoulos MA, San-Miguel J, Belch A, White D, Benboubker L, Cook G, Leiba M, Morton J, Ho PJ, Kim K, Takezako N, Moreau P, Kaufman JL, Sutherland HJ, Lalancette M, Magen H, Iida S, Kim JS, Prince HM, Cochrane T, Oriol A, Bahlis NJ, Chari A, O'Rourke L, Wu K, Schecter JM, Casneuf T, Chiu C, Soong D, Sasser AK, Khokhar NZ, Avet-Loiseau H, Usmani SZ

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX

Haematologica, 103 (12), 2018.

Résumé | Liens:

Laverdiere I, Guillemette C, Tamouza R, Loiseau P, Peffault de Latour R, Robin M, Couture F, Filion A, Lalancette M, Tourancheau A, Charron D, Socie G, Levesque E

Cyclosporine and methotrexate-related pharmacogenomic predictors of acute graft-versus-host disease

Haematologica, 100 (2), 2015.

Résumé | Liens:

Morneau M, Foster W, Lalancette M, Van Nguyen-Huynh T, Renaud MC, Samouelian V, Letarte N, , Almanric K, Boily G, Bouchard P, Boulanger J, Cournoyer G, Couture F, Gervais N, Goulet S, Guay MP, Kavanagh M, Lemieux J, Lesperance B, Ouellet JF, Pineau G, Rajan R, Roy I, Samson B, Sideris L, Vincent F

Adjuvant treatment for endometrial cancer: literature review and recommendations by the Comité de l'évolution des pratiques en oncologie (CEPO)

Gynecol Oncol, 131 (1), 2013.

Résumé | Liens: